BioCina is a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), offering highest-quality, cost-effective cell line, process, analytical and formulation development, and cGMP clinical & commercial manufacturing of the microbial, pDNA and mRNA modalities. BioCina’s first facility in Adelaide, South Australia is a testament to the quality of our work. It has a rich history of developing and manufacturing both clinical and commercial drug substance, backed by most critical SME’s having an average tenure of 15+ years at the site. BioCina boasts an elite quality record, having successfully passed regulatory inspections by the US FDA, Health Canada, and EMA, and is licensed by the Australian TGA for cGMP manufacturing of bulk drug substance or active intermediates, and through our partnership with NovaCina, we are also able to offer our clients a highest-quality fill-and-finish solution. We are proud to have clients based in the U.S., Europe, and the Asia Pacific, and because we are not a drug developer, we only serve our client’s products. Furthermore, we will be establishing a second large-scale, high-capacity end-to-end mammalian and microbial facility in Australia, to be ready for client service in 2026.
In addition, Australia offers one of the most attractive R&D tax incentives available globally (up to 48.5% cash refund), making it an ideal destination for biologics companies looking to invest in research and development of their products.